Boston Scientific cuts 2026 outlook after WATCHMAN and other units weaken; INTERA 3000 pump recall closed
AI مارکیٹ کا خلاصہ
Boston Scientific cut its 2026 full-year guidance, citing weaker-than-expected performance in WATCHMAN, Electrophysiology, and Urology, marking a meaningful near-term earnings reset. A completed Class II recall of a single INTERA 3000 hepatic artery infusion pump appears operationally immaterial, but adds incremental quality-control scrutiny. The combined update pressures the near-term growth narrative and raises execution-risk focus ahead of anticipated 2027–2028 product launches.
اثر کی سطح
● درمیانہ
متاثرہ اثاثے
NCSKBSX2USD/USDT-2.03%
AI تجزیاتی سمجھ · NCSKBSX2USD/USDTAI تجزیاتی سمجھ
▼ Bearish
ابھی ٹریڈ کریں
⚠️ AI سے تیار کردہ تجزیاتی سمجھ خبروں کے مواد پر مبنی ہے اور صرف معلوماتی مقاصد کے لیے فراہم کی گئی ہے۔ یہ سرمایہ کاری کا مشورہ نہیں ہے اور نہ ہی BingX کے خیالات کی نمائندگی کرتی ہے۔ سرمایہ کاری میں رسک شامل ہے۔ براہ کرم ذمہ داری سے ٹریڈ کریں۔
Boston Scientific (BSX) said in July 2026 that it lowered its full-year 2026 guidance after results in WATCHMAN, Electrophysiology and Urology came in weaker than expected. Around the same period, the company completed a U.S. voluntary recall of one INTERA 3000 hepatic artery infusion pump (Serial Number 20175), a Class II action that has been closed. Management reiterated that product launches planned for 2027–2028 could support growth, but the guidance cut—its first in nearly a year—prompted investors to reassess near-term execution risk.
